Company provides details on two highly anticipated acquisitions targeted to close in 2019
DENVER, March 5, 2019 /PRNewswire/ -- Medicine Man Technologies, Inc. (MDCL), a rapidly growing, vertically integrated nationwide cannabis operator, today announced that the Company has issued their February 2019 Letter to Shareholders, highlighting two pending acquisitions of MedPharm Holdings, LLC and Medicine Man Denver, a review of its recent financial and operating performance and details on its strategic goals as a vertically integrated cannabis brand and operator.
Recent Company Highlights include:
"Our shareholder letter addresses our two valuable pending acquisitions of MedPharm Holdings and Medicine Man Denver that will bring Medicine Man Technologies to an annual run rate of over $40 million," says Andy Williams, Co-Founder, Chairman and CEO of Medicine Man Technologies. "These acquisitions will greatly benefit from our existing relationships in 18 states and seven countries. They will also position us to drive revenue through traditional partnerships only reserved for pharmaceutical companies as the only cannabis company with a federal research license. The shareholder letter also details our company processes and resources that will position Medicine Man Technologies to provide turnkey solutions and supplies for cannabis cultivators."
To view Medicine Man Technologies' Shareholder Letter please visit: https://www.medicinemantechnologies.com/investor-information/company-information/
About Medicine Man
Technologies
Medicine Man Technologies is a fully
integrated operator in the cannabis industry, offering consulting,
retail pharma-grade products and turnkey solutions for cannabis
cultivators for over a decade. Medicine Man Technologies is
leveraging its expertise and intellectual property to vertically
integrate retail, cultivation, formulation and distribution
operations. The Company's client portfolio includes active and
past clients in 18 states and seven
countries.
Forward-looking Statements
This press
release contains "forward-looking statements." Such statements may
be preceded by the words "intends," "may," "will," "plans,"
"expects," "anticipates," "projects," "predicts," "estimates,"
"aims," "believes," "hopes," "potential" or similar words.
Forward-looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company's control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (ii) difficulties in
obtaining financing on commercially reasonable terms; (iii) changes
in the size and nature of our competition; (iv) loss of one or more
key executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company's filings with the Securities and Exchange
Commission (SEC), including the Company's Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC's website at http://www.sec.gov. The Company assumes
no obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
View original content:http://www.prnewswire.com/news-releases/medicine-man-technologies-inc-issues-2019-shareholder-letter-300806554.html